Brain cancer vaccine succeeds at prolonging survival in Phase 3 trial

44Report
Brain cancer vaccine succeeds at prolonging survival in Phase 3 trial

A Phase 3 trial for Northwest Biotherapeutics’s DCVax-L vaccine extended survival in patients with gliobastoma for many months, or in some cases, years: according to new data.

Similar news

Share
Report

Report this article here.